The GORE Viabahn Endoprosthesis for the Treatment of Venous Occlusions and Stenoses
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | December 2010 |
| End Date: | June 2015 |
| Contact: | Fizaa Ahmed |
| Email: | fizaa@stanford.edu |
| Phone: | (650)725-6409 |
Evaluation of GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface for the Treatment of Venous Occlusions and Stenoses
To study the safety and efficacy of drug coated stents for the treatment of venous
occlusions and stenoses in the lower extremity. The use of the device for the treatment of
peripheral arterial disease is approved by the FDA, however, the use of the device in venous
occlusions and stenoses, although performed by some practitioners, has not yet been studied
in detail.
occlusions and stenoses in the lower extremity. The use of the device for the treatment of
peripheral arterial disease is approved by the FDA, however, the use of the device in venous
occlusions and stenoses, although performed by some practitioners, has not yet been studied
in detail.
Inclusion Criteria:
- Patient is at least 18 years old
- Patient has clinical manifestations (i.e. symptoms and/or signs) of chronic DVT of an
extremity. The Venous Clinical Severity Score (VCSS) will be used to determine if the
patient is currently suffering from chronic DVT, with a VCSS score of 4 or greater
necessary for inclusion.
- Imaging confirmation of venous occlusion or stenosis (>50%) involving the femoral,
and/or popliteal veins
- Obstructed vessel caliber can accommodate a 7FR System, from insertion site to target
segment
- Patient is able to read and answer a questionnaire in English
Exclusion Criteria:
- History of life-threatening reaction to contrast material
- Unwilling or unable to provide informed consent, or return for required follow-up
evaluations
- Participating in another investigational study that has not completed follow-up
testing
- Cannot receive outpatient anticoagulation such as LMWH and/or vitamin K antagonists
(VKAs)
- Absolute contraindication to contrast media or renal insufficiency (baseline
creatinine >2.0 mg/dL).
- Either a history or presence of heparin-induced thrombocytopenia antibodies
We found this trial at
1
site
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
